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Notch activation. These observations 
in cultured cells are relevant in vivo, as 
residual levels of Dll4 that could poten-
tially suppress angiogenesis are present in 
stalk cells. By antagonizing these signals, 
Jag1 can promote stalk cell activation and 
maintain the VEGF response. Supporting 
evidence for Fringe-mediated regulation 
of angiogenesis also comes from genetic 
deletion of another Fringe family member, 
Lunatic Fringe, in mice. Loss of Lunatic 
Fringe results in enhanced retinal angio-
genesis and increased tip cell numbers, 
indicating reduced Notch activation.
In addition to antagonizing Dll4-medi-
ated activation of Notch signaling, Jag1 
could also promote angiogenesis by sig-
naling directly to tip cells to regulate the 
expression of VEGF receptor 3 (VEGFR3). 
VEGFR3 has a crucial role in mediating 
the growth of lymphatic vessels, but it 
is also expressed in endothelial tip cells 
where it promotes angiogenesis. Indeed, 
a recent study has shown that disrup-
tion of VEGFR3 function in endothelial tip 
cells using monoclonal antibodies blocks 
vascular sprouting (Tammela et al., 2008). 
Benedito et al. show that VEGFR3 expres-
sion in tip cells is decreased when Jag1 is 
deleted, providing a mechanistic explana-
tion for why these tip cells could have an 
impaired sprouting response. Thus, one 
could envision that, just as Dll4-Notch 
signaling downregulates expression of 
the VEGF receptor in stalk cells to inhibit 
vessel growth, Jag1-Notch signaling could 
upregulate VEGFR3 expression in tip cells 
to promote vessel growth.
A key question arising from this work 
is how Jag1 and Fringe family members 
are themselves regulated in endothelial 
cells. Jag1 expression can be induced 
in vitro by inflammatory factors such as 
tumor necrosis factor α, which could pro-
vide a means for integrating signals from 
the local microenvironment to promote 
new vessel growth (Sainson et al., 2008). 
Evidence from the study of Benedito et 
al. suggests that Fringe is not expressed 
uniformly in sprouting vessels but is found 
in subsets of stalk and tip cells. Given the 
crucial roles that Fringe members could 
play in regulating angiogenesis, under-
standing the upstream factors that control 
their expression will be essential to fur-
ther unraveling their function. Lastly, Jag1 
clearly plays additional roles during angio-
genesis beyond those in tip and stalk cell 
selection, and it also functions in tissues 
other than blood vessels (Hofmann and 
Iruela-Arispe, 2007). In humans, for exam-
ple, haploinsufficiency of Jag1 causes 
Alagille Syndrome, which is character-
ized by abnormalities in the cardiovascu-
lar system, liver, eye, and skeleton (Grid-
ley, 2003). The ability to selectively delete 
Jag1 in different tissues and at different 
developmental stages in model organisms 
should allow more detailed investigation of 
the pathogenesis of this disease.
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The loss of expression of particular microRNAs can contribute to tumorigenesis. Kota et al. (2009) 
now explore in a mouse model a promising new approach for the treatment of liver cancer— 
re-establishing the expression of an miRNA using a viral vector.MicroRNAs (miRNAs) play fundamental 
roles in the regulation of gene expression 
by pairing via partial Watson Crick inter-
actions with complementary sequences 990 Cell 137, June 12, 2009 ©2009 Elsevier within the 3′ untranslated regions (UTRs) 
of targeted transcripts (Bartel and Chen, 
2004; Bartel, 2009). There are now 
numerous examples linking dysregu-Inc.lated expression of miRNAs to cancer, 
and miRNAs are increasingly viewed 
as potential therapeutic targets. In this 
issue, Kota et al. (2009) demonstrate in 
a mouse model of liver cancer that ecto-
pic expression of a single miRNA, miR-
26a, can reverse disease progression. 
This report represents an important 
step toward the potential application of 
microRNA-based therapy for the treat-
ment of cancers.
The importance of miRNAs in fine-
tuning gene expression is highlighted by 
the demonstration that changes in the 
abundance of a single miRNA can affect 
the levels of expression of hundreds of 
different proteins (Baek et al., 2008; Sel-
bach et al., 2008). Thus, it is not surpris-
ing that a single dysregulated miRNA 
can push cells into a transformed state. 
In prior work, Mendell and colleagues 
have demonstrated that MYC-induced 
liver tumors in mice result in concomitant 
downregulation of a number of miRNAs, 
including miR-15a/16, miR-26a, miR-
34a, miR-150, and miR-195 (Chang et 
al., 2008). In the current study by Men-
dell and colleagues (Kota et al., 2009), 
the miRNA whose expression is most 
perturbed in the MYC-induced hepato-
carinoma is miR-26a. The authors show 
that miR-26a regulates the expression of 
the cyclins D2 and E2 and induces a G1 
arrest of human liver cancer cells. Hence, 
reduced expression of this miRNA is 
likely to perturb the normal cell-cycle 
control of hepatocytes.
These investigators asked whether 
or not forced expression of miR-26a 
impacts the proliferation of transformed 
hepatocytes. To test this possibility, they 
first ectopically expressed miR-26a in a 
human hepatocellular carcinoma cell 
line (HepG2 cells) using a murine ret-
roviral vector to transduce the miRNA 
encoding gene. They then carried out 
analyses using flow cytometry to deter-
mine if forced expression of miR-26a 
affects the cell cycle of the HepG2 cells 
relative to an empty vector or forced 
expression of an irrelevant miRNA. 
They observe that forced expression of 
miR-26a, but not the control constructs, 
results in increased numbers of cells in 
the G1 stage of the cell cycle and fewer 
cells in the proliferative S phase. Given 
this biological effect of miR-26a expres-
sion they systematically examined the 
levels of miR-26a in paired biopsies 
from normal human liver tissue versus 
human liver cancer samples. These 
studies revealed a consistent reduction in the levels of this miRNA in the cancer 
cells versus normal cells in 7 out of 8 
samples tested.
To further investigate the therapeutic 
potential of miR-26a for hepatocarcinoma, 
Kota et al. take advantage of a mouse 
model of hepatocarcinoma in which 
expression of human MYC is induced by 
tetracycline. Mice harboring the inducible 
human MYC transgene develop hepatic 
cancer following the administration of the 
tetracycline analog doxycycline. Impor-
tantly, MYC does not harbor a miR-26a 
figure 1. miR-26a Triggers cell-cycle Arrest
Adeno-associated viruses (AAV) exist as epi-
somal DNA in the nucleus of cells. A primary 
miR-26a transcript expressed by the viral vector 
is processed by Drosha/DGCR8 and is exported 
to cytoplasm where the pre-miRNA is further 
processed by Dicer/TRBP. The guide strand is 
selected for entry into the RNA-induced silenc-
ing complex (RISC). The miR-26a guide strands 
pairs with sequences in the 3′ untranslated 
regions (UTRs) of target transcripts encoding 
the cyclins D2 and E2, thereby reducing their 
expression. This results in the arrest of cells in 
G1 and inhibits proliferation of hepatocarcinoma 
cells.Cell complementary site in its 3′ UTR, thus 
eliminating this message as a potential 
target for miR-26a. The next problem that 
confronted the investigators was to deliver 
a miR-26a construct into hepatocytes in 
vivo. The solution is provided by an adeno-
associated virus (AAV) vector, which is 
highly efficient at transducing hepatocytes 
in vivo (Figure 1). Kota et al. placed the 
miR-26a pre-miRNA in an intron associ-
ated with the elongation factor 1 alpha 
(EF1α) transcription unit, which in turn was 
fused to an enhanced green fluorescent 
(EGFP) reporter. Transduced cells can then 
be monitored by the expression of green 
fluorescence. The AAV vectors harboring 
the miR-26a-EGFP transcription unit as 
well as control vectors are packaged using 
the AAV8 envelope. This envelope is not 
known to be associated with human AAV 
infections, so immunologic memory should 
not be a problem for using this vector clini-
cally. This is an important point given that 
the use of AAV2 for in vivo therapy is lim-
ited by early immunologic memory of AAV 
infections (Mingozzi et al., 2007).
The critical experiment involves the 
use of this vector to transduce cells in 
the mouse model of liver cancer. At a 
critical time following tumor induction, 
doxycycline is withdrawn and the AAV 
constructs are delivered by intravenous 
injection. The majority of this vector local-
izes to the liver and transduces upwards 
of 90% of the hepatocytes. The results 
from these experiments show that 6 out 
of 10 mice treated with the control vector 
lacking the miR-26a construct developed 
liver cancer. In contrast, 8 out of 10 ani-
mals treated with the miR-26a construct 
did not develop disease, and the 2 ani-
mals with disease showed lower trans-
duction efficiency of the vector. Animals 
transduced with the miR-26a construct 
exhibit apoptosis in the cancer cells, but 
remarkably the miRNA does not induce 
apoptosis in nonmalignant hepatocytes.
Taken together, the results are quite 
remarkable. First, the tumor regression 
suggests that this miRNA potently regu-
lates cellular proliferation. Nonmalignant 
hepatocytes are not affected by the 
ectopic expression of this miRNA, con-
sistent with its high level of expression 
in normal hepatocytes. The administra-
tion of miR-26a by an AAV vector is a key 
component of this study. The many new 
serotypes of AAV now available should 137, June 12, 2009 ©2009 Elsevier Inc. 991
expand the potential clinical applications 
of this vector. Most importantly, this 
work convincingly demonstrates that 
ectopic expression of a single miRNA 
can markedly impact a disease, in this 
case hepatic cancer. AAV vectors can 
be produced in large quantities making it 
highly suitable as a gene therapy vector. 
Given that AAV vectors do not integrate 
into the host genome, they will eventu-
ally be eliminated, thereby minimizing 
the potential of vector-mediated tox-
icities. What is truly exciting about this 
study is the strong correlation between 
miR-26a expression and suppression of 992 Cell 137, June 12, 2009 ©2009 Elsevier
Successful thieves select targets care-
fully, knowing that a well-guarded estab-
lishment is unlikely to surrender the loot. 
Oncogenic insults are like thieves in this 
regard, as their effect is highly dependent 
on cell type. Their mission is more likely to 
succeed in a cell where the defenses, such 
as death, terminal differentiation, senes-
cence, or sensitivity to immune surveil-
lance, are weaker. The last few decades 
have exposed most of the culprits, a 
scurrilous cast of activated oncogenes 
and inactivated tumor suppressors, but 
the cell-specific weaknesses—the inside 
crew—that allow them to flourish are more 
mysterious.
Now, David Cobrinik and colleagues 
redress this balance for the childhood 
ocular cancer, retinoblastoma (Xu et al., 
2009). This tumor is initiated by inactiva-
tion of both copies of retinoblastoma 1 
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Why are some cell types more p
show that retinoblastoma cells c
survival and growth.hepatic cancer. Restoring miR-26a levels 
in hepatic cancer cells via transduction 
with AAV vectors is clearly a path to the 
clinic that will be exploited given the high 
prevalence of liver cancer worldwide. 
The use of a natural miRNA to suppress 
cell proliferation is exciting and hopefully 
will lead to a new therapeutic strategy for 
the treatment of liver cancer.
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(RB1) and helped along by subsequent 
genetic events (Figure 1A) (Corson and 
Gallie, 2007). Xu et al. now expose a quar-
tet of insiders that help these oncogenic 
events to take hold: N-Myc, MDM2, and 
the nuclear receptors RXRγ and THRβ2 
(Figure 1B). Although their presence is 
essential for tumorigenesis, they are 
not altered by any genetic, epigenetic, 
or posttranscriptional events typically 
associated with oncogene activation.
To expose retinoblastoma’s col-
laborators, the authors first defined the 
predominant cell type in retinoblas-
toma. Prior studies generated conflict-
ing conclusions, failing to distinguish 
normal versus tumor cells. This issue is 
elegantly resolved by Xu et al., who in 
one approach follow RB protein to mark 
normal cells, and in an even better strat-
egy select tumors with a homozygous 
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ture 455, 58–63.RB1 deletion and used fluorescent in situ 
hybridization to distinguish null tumor 
from normal cells. Colabeling reveals 
that most RB1-deficient tumor cells 
resemble cone photoreceptors, the cells 
that allow us to see color. Markers pres-
ent include the retinoic acid-activated 
nuclear receptor RXRγ and the home-
odomain protein CRX (which are also 
expressed in some other retinal neu-
rons) as well as the cone-specific thy-
roid hormone-activated nuclear recep-
tor, THRβ2, and two opsins. Humans 
have three types of cones with distinct 
opsins that detect blue (short wave, S), 
green (medium wave, M), and red (long 
wave, L) light. Xu et al. show that retino-
blastoma is replete with markers of M/L 
cones. This fits well with the presence of 
THRβ2, which blocks S and promotes 
L/M cones (Ng et al., 2001).
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